(71) Applicant: UNIVERSITY COURT OF THE UNIVER-
SITY OF ST ANDREWS [GB/GB]; College Gate, North
Street, St Andrews Fife KY16 9AJ (GB).

(72) Inventors: ZYSMAN-COLMAN, Eli; School of Chem-
istry, University of St. Andrews, North Haugh, St Andrews
Fife KY16 9ST (GB). WONG, Michael Yin; School of
Chemistry, University of St Andrews, North Haugh, St An-
drews Fife KY16 9ST (GB).

(74) Agent: MCPHERSON, Michael; Marks & Clerk LLP,
Atholl Exchange, 6 Canning Street, Edinburgh EH3 8EG
(GB).

(54) Title: LIGHT EMITTING DEVICES AND COMPOUNDS

Fig. 2

Ca(20 nm)/Al (100 nm)

B3PYMPM (50 nm)

Emissive layer (~ 30 nm)

PVK (30 nm)

PEDOT:PSS (30 nm)

ITO

Glass

(57) Abstract: Thermally Activated Delayed Fluorescence (TADF) compounds wherein two aromatic heterocyclic moieties are
provided as acceptor groups, spaced apart from two donor moieties by an aromatic spacer ring, are described. Charged organic
TADF species having a similar structure are also described. The TADF compounds and charged organic TADF species may be em-
ployed as emitter material in light emitting devices such as OLEDs and LEECs. Also described TADF compounds wherein at least
one donor moiety is substituted by at least one substituent that is a phosphine oxide or a phosphine sulphide.

1

Light Emitting Devices and Compounds

Field of the Invention

The present invention is directed to the provision of Thermally Activated Delayed
5   Fluorescence (TADF) compounds for use in OLEDs or other light emitting devices..

Background to the Invention

Organic Light Emitting Diodes (OLEDs) have come to the fore as the state-of-the-art
technology for visual displays and lighting. OLEDs are desirable as they are light-
10   weight, flexible, provide better contrast and possess large viewing angle. OLEDs are
also more power efficient than traditional lighting sources and thus their wide adoption
can alleviate significantly the strain on current energy demand because lighting alone
constitutes about 20% of energy consumption worldwide.

15   The "first generation" OLEDs were based on organic fluorescent emitters whose
efficiency was intrinsically capped at 25% due to only being able to recruit singlet
excitons. The "second generation" OLEDs employed organometallic phosphorescent
emitters, which harvest both singlet and triplet excitons for emission due to the
enhanced intersystem crossing (ISC) mediated by the large spin-orbit coupling of
20   heavy metals such as iridium(III) and platinum(II). Despite their highly desirable
performance characteristics, the rarity of these metals, their high cost and their toxicity
are important detracting features that inhibit large-scale, worldwide adoption of OLED
technology.

25   The "third generation" OLEDs were recently first reported by Adachi and co-workers.
His group demonstrated how small organic molecules, emitting via a thermally
activated delayed fluorescence (TADF) mechanism, could be integrated into OLEDs
and exhibit very high efficiencies as, like with phosphorescent emitters, both singlet
and triplet excitons are recruited for emission (Reference 1). Thus, TADF-based
30   OLEDs address the key detracting features endemic to "second generation" OLEDs
while retaining their advantages (Reference 2).

The principle of TADF relies on a small energy gap between the lowest singlet and
triplet excited states (ΔE_{ST}). Under these conditions, the electrons in the triplet state
35   can return to the singlet state by reverse intersystem crossing (RISC) using thermal

2

energy, followed by radiative fluorescence (Reference 1a). The small ΔE_{ST} is realized by spatial separation between HOMO and LUMO to minimize the electronic repulsion between these orbitals. A large number of organic TADF emitters have been reported to date. They can make use of donor and acceptor moieties of various types within the molecule to achieve the desired small energy gap between the lowest singlet and triplet excited states (ΔE_{ST}). The majority of these molecules are based on a twisted intramolecular charge transfer (TICT) design in which the donor and acceptor moieties are designed to be nearly orthogonal to each other (References 1a, 1c and 3).

Despite the progress made there is a need to provide improved and alternative compounds for use in display and lighting uses, such as in organic light emitting diodes (OLEDs) and light emitting electrochemical cells (LEECs).

Description of the Invention

According to a first aspect, the present invention provides a compound according to formula I:

I

wherein the ring II:

II

represents an aromatic spacer ring with each Het bonded to adjacent carbon atoms and each moiety D bonded to adjacent carbon atoms, and
wherein each Het is an aromatic heterocyclic moiety and each D is a donor moiety.

3

The compound according to formula I exhibits TADF behaviour. The aromatic heterocyclic groups Het act as acceptor groups and the donor moieties D act as donor groups. The spatial separation of Het and D by the ring II provides segregation of the HOMO (centred on donors D) and LUMO (centred on acceptors Het) that provides

5   efficient TADF behaviour.

The ring II may be a benzene ring and thus the compound of the invention may be according to formula III:

III

10   wherein D and Het have the same meaning as before. R* may be , independently for each occurrence, selected from the group consisting of –H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

The aromatic heterocyclic moieties Het may be, independently for each occurrence selected from the group consisting of:

15

wherein –L represents the bonding position to ring II or III, X represents O, S or NR^2 and groups R^2 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that

20   may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl;

wherein groups R^1 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4);

4

substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide, phosphine sulphide and the like.

Where the group R^1 is amino it may be $-NH_2$, -NHR or $-NR_2$, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Where the groups R^*, R^1 or R^2 (or any other groups such as R, and R^3 to R^9 provided in structures discussed herein), are described as substituted they may be independently substituted for each occurrence. For example once, twice, or three times, e.g. once, i.e. formally replacing one or more hydrogen atoms with substituents such as halo (e.g. fluoro, chloro, bromo and iodo),$-SF_5$, $-CF_3$, -OMe, $-NO_2$, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where the substituent is amino it may be NH_2, NHR or NR_2, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

By aryl is meant herein a radical formed formally by abstraction of a hydrogen atom from an aromatic compound. As known to those skilled in the art, heteroaryl moieties are a subset of aryl moieties that comprise one or more heteroatoms, typically O, N or S, in place of one or more carbon atoms and any hydrogen atoms attached thereto. Exemplary aryl substituents, for example, include phenyl or naphthyl that may be substituted.   Exemplary heteroaryl substituents, for example, include pyridinyl, furanyl, pyrrolyl and pyrimidinyl.

Further examples of heteroaromatic rings include pyridazinyl (in which 2 nitrogen atoms are adjacent in an aromatic 6-membered ring); pyrazinyl (in which 2 nitrogens are 1,4-disposed in a 6-membered aromatic ring); pyrimidinyl (in which 2 nitrogen atoms are 1,3-disposed in a 6-membered aromatic ring); or 1,3,5-triazinyl (in which 3 nitrogen atoms are 1,3,5-disposed in a 6-membered aromatic ring).

5

Where the group R*, R^1 or R^2 (or any of the groups R, R^3 to R^9 provided in structures discussed herein), includes one or more rings they may be cycloalkyl they may be for example cyclohexyl or cyclopentyl rings. The cyclohexyl or cyclopentyl groups if present may be saturated or unsaturated and may be substituted as described above.

5   Examples of aromatic heterocyclic moieties Het include 1,3,4 oxadiazoles:

wherein–L represents the bonding position to ring II or III;

-Alkyl represents a substituted or unsubstituted primary , secondary or tertiary

10   alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); and wherein groups R^3, R^4 and R^5 are, independently for each occurrence selected from the group consisting of :

-H, substituted or unsubstituted primary, secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or

15   unsubstituted aryl or heteroaryl, -CF$_3$, -OMe,   -SF$_5$, -NO$_2$, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide, phosphine sulphide and the like.

20   D are donor moieties that may take several different forms as known in the field of TADF compounds. They may be the same or different for each occurrence

For example donor moieties D may be:

25

6

wherein –L represents the bonding position to ring II or III;

each group R^6, R^7, R^8 and R^9 is, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide, phosphine sulphide and the like.

Where the group (one or more of R^6, R^7, R^8 and R^9) is amino it may be $-NH_2$, -NHR or - NR_2, where the substituents R on the nitrogen may be substituted or unsubstituted alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Where the group (one or more of R^6, R^7, R^8 and R^9) is phosphine oxide or phosphine sulphide it may be selected from the group consisting of:

and where the substituents R on the phosphorus may be substituted or unsubstituted alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

The phosphine oxide or phosphine sulphide substituent may be para to the nitrogen of the carbazole structure i.e. one or both of R^8 may be a phosphine oxide or phosphine sulphide substituent. Conveniently where both R^8 are a phosphine oxide or phosphine sulphide substituent they may be the same. The phosphine oxide or phosphine sulphide substituent may have phenyl or substituted phenyl groups R on the phosphorus.

Thus substituents:

 and , or substituents where one or both phenyl groups are substituted, are contemplated for donor moieties D.

7

Phosphine oxide or phosphine sulphide may be used as acceptor moieties, or part of acceptor moieties (substituents on acceptor moieties) in the structure of a TADF molecule, such as the TADF compounds described herein.

5   Where used as a substituent on a donor moiety D as described herein, phosphine oxide or phosphine sulphide acts to moderate the character of the donor and can therefore alter the photo physical behaviour of a TADF compound, for example resulting in a change in colour and or intensity of emission. The use of phosphine oxide or phosphine sulphide as a substituent on a donor moiety D of a TADF

10   compound, such as the compounds described herein constitutes another aspect of the invention.

More generally moieties D may also be selected from:

8

wherein –L represents the bonding position to ring II or III, that is para to the nitrogen in structures C, D, G and H;

X^1 is selected from the group consisting of O, S, NR, SiR_2, PR and CR_2, wherein each R is independently selected from the group consisting of –H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10);

each Ar is independently for each occurrence selected from the group consisting of substituted or unsubstituted aryl or heteroaryl; and

represents, independently for each occurrence a substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A B, C, D, E or F for example a five or a six membered substituted or unsubstituted aryl or heteroaryl ring; and

9

n ( ) indicates the optional presence of saturated $-CH_2-$ groups in the rings annelated to the benzene ring, wherein n is independently for each occurrence, 0, 1, or 2.

Substituents on $-Ar$ and , where present can include phosphine oxide or phosphine sulphide, as discussed above, to moderate the donor properties.

Thus moieties D may be selected from:

 , and

 ,

wherein the groups R^6 , R^7, R^8 and R^9 may take the same meaning as before.
The saturated rings annelated to the benzene ring in the structure:

 may be five six or seven membered rings. Typically they may be six membered, i.e. the juliolidine structure, where n is 1:

 .

10

Exemplary compounds include structures IV, V and VI, below, where the moieties Het are 1,3,4 oxadiazoles and the donor moieties D are carbazole:

| IV | V | VI |

5   In comparison with the known TADF emitter "2CzPN":

2CzPN   these compounds exhibit improved TADF properties as described below, under the heading "Detailed Description of Some Embodiments and Experimental Results".

10   In general the weaker acceptor strength of the moieties Het compared with cyano groups provides a bluer emission, considering the intramolecular charge transfer (ICT) nature of emission in TADF emitters. Furthermore, according to DFT calculations, the LUMO density of 2CzPN is mostly located on the central benzene ring whereas that of Het moieties such as oxadiazoles may be expected to be located on the heterocyclic

15   ring. This implies that the electron density of HOMO and LUMO in compounds of the invention should be more segregated than in 2CzPN, resulting in more efficient TADF. Indeed, all these expectations are fulfilled as supported by the blue-shifted emission and shorter emission lifetime of the delayed component of emission exhibited by IV, V and VI, when compared with the prior art 2CzPN.

20

The synthesis of compounds according to the first aspect of the invention can be achieved by those skilled in the art. For example, and as illustrated by examples provided hereafter, the groups Het can be formed on an existing TADF structure by reaction at a nitrile. Other means of building or attaching groups Het to an aromatic

11

(spacer) ring are well known. Similarly methods for attaching donor moieties D to an aromatic (spacer) ring are available to the skilled person. (For example in: Name reactions in heterocyclic chemistry 2005 – Jie jack Li, editor; Wiley; and Strategic Applications of Organic Named Reactions in Organic Synthesis 2005 - by Laslo Kurti and Barbara Czako; Academic Press.   The content of these documents are incorporated by reference herein). Conveniently the addition of donor moieties D may be by nucleophilic aromatic substitution reactions such as are employed to provide carbazole substituents on prior art TADF molecules like 2CzPN.

The use of different donor moieties D on the compounds of the invention affords the opportunity to adjust the photo physical properties of TADF structures. More generally the donor moieties described herein can provide useful alternatives to the carbazole or modified carbazole moieties typically employed in some prior art TADF structures such as 2CzPN.   Thus according to a second aspect the present invention provides a compound according to formula Ic:

Acc   Acc
    \   /
     C – C
    /   \
(   )
    \   /
     C – C
    /   \
   D   D

Ic

wherein the ring II:

     \   /
      C – C
     /   \
 (   )
     \   /
      C – C
   /   \

II

represents an aromatic spacer ring wherein each Acc is an acceptor moiety with each acceptor moiety Acc bonded to adjacent carbon atoms, each D is a donor moiety and each donor moiety D bonded to adjacent carbon atoms, and
wherein one of the donor moieties D is according to formula A and the other is according to formula A or according to formula B :

12

A   B

wherein −L represents the bonding position to ring II;

X^1 is selected from the group consisting of O, S, NR, SiR_2, PR and CR_2, wherein each R is independently selected from the group consisting of −H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10); and

 represents, independently for each occurrence a substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A or B, for example a five or a six membered substituted or unsubstituted aryl or heteroaryl ring.

Substituents on , where present, can include phosphine oxide or phosphine sulphide, as discussed above, to moderate the donor properties.

The ring II may be a benzene ring and thus the compound of formula Ic may be according to formula IIIc:

IIIc   wherein D and Acc have the same meaning as before. R* may be , independently for each occurrence, selected from the group consisting of −H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10

The compounds according to formula Ic or IIIc exhibit TADF behaviour. The acceptor moieties Acc act as acceptor groups and the donor moieties D act as donor groups. The spatial separation of Acc and D by the ring II provides segregation of the HOMO

13

(centred on donors D) and LUMO (centred on acceptors Acc) that provides efficient TADF behaviour.

The donor moieties according to formula A may moderate the photo physical behaviour of the TADF structure and can provide improved robustness to the molecules. Prior art typical TADF structures make use of only carbazole derived donor moieties D when having a similar "cruciform" structure – two acceptor groups and two donor groups as depicted in formula Ic. Moderation of the photo physical properties can include shifting of the emission spectra towards the red end of the spectrum. This effect can be related to the increased donor strength provided by donor groups D. Thus this aspect of the invention allows the production of light emitting devices based on the general structure of formula Ic with red shifted, including red, emission spectra.

The acceptor moieties Acc may be selected from the group consisting of acceptor moieties Het as described herein, -CN and other acceptors such as sulfoxide, imine, amide, sulfone, acridine, acridinium, carboxylate ester, phosphine oxide, phosphine sulfide, ketone and aldehyde. Conveniently the acceptor moieties may both be the same. Alternatively they may be different.

The moieties D of formula A in formula Ic may be selected from:

wherein the groups R, R^6, R^7, R^8 and R^9 may take the same meaning as before.

25

14

Examples of compounds according to formula Ic include compounds of formulas VIII, IX and X:

| VIII | IX | X |
| (PXZ)₂PN | (PTZ)₂PN | CzPTZPN |

In these compounds acceptor groups Acc are –CN and donor moieties D employed are phenoxazine (VIII), phenothiazine (IX) and both phenothiazine and carbazole (X). To further modify the properties of these structures, the nitrile acceptor moieties –CN may be modified as described herein and in accordance with the first aspect of the invention to be acceptor moieties –Het.

According to a third aspect the present invention provides a charged organic species according to formula Ia:

Ia

wherein the ring II:

II

represents an aromatic spacer ring with each Het bonded to adjacent carbon atoms and each moiety D bonded to adjacent carbon atoms;

15

wherein each Het is an aromatic heterocyclic moiety and each D is a donor moiety.

Sufficient counter ions C are provided to balance the charge on the charged species of formula Ia.

The charged organic species according to formula Ia exhibits TADF behaviour. The aromatic heterocyclic groups Het act as acceptor groups and the donor moieties D act as donor groups. The spatial separation of Het and D by the ring II provides segregation of the HOMO (centred on donors D) and LUMO (centred on acceptors Het) that provides efficient TADF behaviour.

Thus organic salts of the form Ib:

Ib

where C is a counter ion with opposite charge to that provided on the ring structure including the groups Het and D, and n is at least one, can be employed in OLEDs by virtue of their TADF behaviour. In addition they may be employed in use in a LEEC, by virtue of the charge and corresponding counter ions.

The TADF species Ia can provide the benefits in terms of high efficiencies found with OLED devices but in use in a LEEC, by virtue of the charge and corresponding counter ions. (i.e. salts Ib). The charged organic thermally activated delayed fluorescence (TADF) species Ia and its accompanying counter ions can present the advantage of good solubility allowing solution processing, for example inkjet type printing when fabricating display devices, especially when fabricating large displays. Other benefits of LEECs can be realised, such as the ability to fabricate the device in air and the ability to use air stable electrodes.

The charged species of the invention may be according to formula IIIa:

16

IIIa

wherein D and Het have the same meaning as for formula Ia. R* may be, independently for each occurrence, selected from the group consisting of –H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10; the aromatic heterocyclic moieties Het may be, independently for each occurrence selected from the group consisting of:

and

;

wherein –L represents the bonding position to ring II or III, X represents O, S or NR^2 and groups R^2 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl;

wherein groups R^1 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, -CF$_3$, -OMe, -SF$_5$, -NO$_2$, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide, phosphine sulphide and the like;

and wherein at least one of the occurrences R* and R^1 represents the bonding position, either directly or via a linking group L, to a charged group Z

and/or at least one of the donor moieties D includes a charged group Z directly attached or attached via a linking group L.

17

Moieties D and Het in the charged species may take the form described above with respect to the first aspect of the invention.

5   The linking group L is optional for each occurrence of groups Z.   Conveniently where linking groups L are employed, one is used for each group Z.

Where present the linking group L may, independently for each occurrence, comprise or consist of a hydrocarbylene chain, for example C1 to C30 or even C1 to C10, that
10   may be substituted or unsubstituted, hydrocarbylene or unsaturated hydrocarbylene. The hydrocarbylene chain can include substituted or unsubstituted saturated, unsaturated or aromatic rings. For example the hydrocarbylene chain may include or consist of substituted or unsubstituted cyclopentane-1,3-diyl, cyclohexane-1,4-diyl, 1,4-phenylene or 4,4'-biphenylene moieties. Aromatic rings where present may be aryl or
15   heteroaryl.

Where the linking group L is substituted it may be independently substituted for each occurrence. For example once, twice, or three times, e.g. once, i.e. formally replacing one or more hydrogen atoms of the hydrocarbylene chain. Examples of such
20   substituents are halo (e.g. fluoro, chloro, bromo and iodo),-SF$_5$, -CF$_3$, -OMe,
-NO$_2$, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where
25   the substituent is amino it may be NH$_2$, NHR or NR$_2$, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

In addition to substitution options for linking groups L as discussed above, similar
30   options for substitution may be employed for other groups or substituents that may be substituted or unsubstituted as described herein. Thus groups that may be substituted may be, for example, substituted once, twice, or three times, e.g. once, i.e. formally replacing one or more hydrogen atoms of the group. Examples of such substituents are halo (e.g. fluoro, chloro, bromo and iodo),-SF$_5$, -CF$_3$, -OMe, -NO$_2$, substituted or
35   unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be

18

unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where the substituent is amino it may be NH_2, NHR or NR_2, where the substituents R on the nitrogen may be

5   alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Where the linking group includes one or more rings they may be cycloalkyl they may be for example cyclohexyl or cyclopentyl rings. The cyclohexyl or cyclopentyl groups if

10   present may be saturated or unsaturated and may be substituted as described above.

A linking group L may also include heteroatoms in a hydrocarbylene chain, for example by substituting one or more carbon atoms in the chain e.g. one, two, or three carbon

15   atoms with any one of O, N, or S for example.

Examples of unsubstituted hydrocarbylene chains for group L include:

$-CH_2-(CH_2)_n-$, wherein n is from 0 to 10 or even 0 to 5 and optionally containing one or more unsaturations; cyclopentane-1,3-diyl; cyclohexane-1,4-diyl; 1,4-phenylene;

20   4,4'-biphenylene.

Non-metal charged groups Z may be, independently for each occurrence, positively or negatively charged. Counter ions C will have the opposite charge.

25   Where groups Z are positively charged they may be, independently for each occurrence, selected from the group consisting of quaternary nitrogen cations, and quaternary phosphorus cations. Conveniently all groups Z will be the same.

Where groups Z are negatively charged they may be provided with anionic substituents

30   such as carboxylate, sulfonate, sulfinate, phosphonate, cyanide and thiocyanate.

Examples of quaternary nitrogen groups Z include:

19

1

2

3

4

wherein –L indicates the position of bonding to a linking group L or directly to a charged moiety of formula Ia or IIIa; R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{10} are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where the substituent is amino it may be NH_2, NHR or NR_2, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Where the quaternary nitrogen is pyridynyl as in structure 3 the attachment to linking group L or directly to a TADF moiety may be to a carbon rather than to the nitrogen, Thus the quaternary nitrogen group Z may take the form of structure 5:

20

5

wherein one of R^8, R^9, R^{10} and R^{11} bonds to a linking group L or directly to a TADF moiety and the others of R^8, R^9, R^{10} and R^{11}, independently for each occurrence selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, -CF_3, -OMe, -SF_5, -NO_2, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where the substituent is amino it may be NH_2, NHR or NR_2, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Where groups R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{10} are aryl, heteroaryl or cycloalkyl and are substituted, they may be substituted with substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, -CF_3, -OMe, -SF_5, -NO_2, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate and the like. Where the substituent is amino it may be NH_2, NHR or NR_2, where the substituents R on the nitrogen may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

Thus examples of quaternary nitrogen groups Z include:

21

wherein –L indicates the position of bonding to a linking group L or directly to a TADF moiety.

Examples of quaternary phosphorus groups Z include:

6

wherein R^1, R^2 and R^3 have the same meaning as for the corresponding quaternary nitrogen group 1 discussed above and wherein –L indicates the position of bonding to a linking group L or directly to a TADF moiety.

Thus examples of quaternary phosphorus groups Z include:

22

wherein –L indicates the position of bonding to a linking group L or directly to a TADF moiety.

The counter ion or counter ions C may be selected from the group consisting of: halide, PF_6^-, BF_4^-, BR_4^-; wherein R is an aryl group, for example phenyl; OTf$^-$, OTs$^-$, SbX_6^- wherein X is halide, NTf_2^- NO_3^-, CO_3^{2-}; cations of first and second group elements in the periodic table and quaternary ammonium cations.

23

Exemplary structures according to the second aspect of the invention may take the same form as those discussed above with respect to the first aspect of the invention, with the addition of at least one charged group Z, each optionally attached by a linking group L.

5

For example, where a carbazole moiety is used as donor moiety D the charged species may take the general form VII:

VII

10   wherein at least one of groups R^8 (para to the carbazole nitrogen) is of the form –L-Z wherein L is a linking group and Z a charged group as discussed herein.

Synthesis of the charged organic thermally activated delayed fluorescence (TADF) species and sufficient counter ions to balance the charge on the charged organic

15   thermally activated delayed fluorescence (TADF) species can be carried out by a skilled person.

These salts may be made by modification of the TADF species to provide charged species and the desired counter ion or counter ions may be present in the synthetic

20   route to the charged species or introduced by suitable ion exchange procedures.

For example, carbazole or similar donor moieties D of the TADF molecules may be modified before and/or after synthesis of the TADF molecule to provide a charged group or groups.

25

An exemplary synthetic route is shown below in Scheme A.

Scheme A. Synthesis of charged TADF emitters. a. NBS, ACN, rt, 1 h. b. i) NaH, THF, rt, 30 min, ii) TBDMSiCl c. i) *n*-BuLi, THF, -78 °C, 30 min, ii) excess 1,4-diiodobutane. d. NaH, imidazole, THF, reflux, 4 h. e. i) NaH, **4**, THF, rt, 30 min, ii) 2 equiv. 4,5-difluorophthalonitrile, rt, 4 h. f. i) NaH, **4**, THF, rt, 30 min, ii) 0.6 equiv. 4,5-difluorophthalonitrile, rt, 4 h. g. i) MeI, ACN, 40 °C, 2h ii) sat. NH4PF6 (aq).

25

In the examples shown in the scheme A above carbazole, used as donor moiety, is modified by bromination to provide 3-bromocarbazole **1** . The TBDMS protected intermediate **2** is alkylated with an iodo-hydrocarbylene group to give intermediate **3**. Alkylation with imidazole provides modified carbazole **4**. As shown in the scheme, the

5   modified carbazole 4 can be used to provide TADF species **5** or **6**. Quaternisation of imidazole nitrogen with methyl iodide and then exchange of iodide anion with PF_6 provides **7** and **8**.

This general approach can be used to provide other TADF species with charged

10   groups, optionally connected by linking groups such as hydrocarbylene linkers. For example the other donor moieties D discussed herein may be modified by synthetic routes akin to that of scheme A to add charged groups, optionally connected by linking groups. Quaternisation at N or P provides a convenient route to charged (cationic) species. Alternatively providing anionic charged species (optionally connected by

15   linking groups L) such as carboxylate, sulfonate, sulfinate, phosphonate, cyanide and thiocyanate can be readily done by the skilled person.

Modification of the -CN groups to produce -Het groups can be carried out before or after addition of the donor groups.

20

The present invention also provides an OLED or other light emitting device, such as a LEEC comprising a compound or charged organic species of the invention.

According to a fourth aspect the present invention provides a TADF compound wherein

25   at least one donor moiety (D) is substituted by at least one substituent selected from the group consisting of phosphine oxide and phosphine sulphide. Conveniently where more than one phosphine oxide or phosphine sulphide substituent is provided they may be the same. Alternatively they may be different. Where the TADF compound has more than one donor moiety (D) then all the donor moieties D may be provided with

30   one or more phosphine oxide or phosphine sulphide substituents.

The phosphine oxide or phosphine sulphide substituent may be selected from the group consisting of:

26

 and where the substituents R on the phosphorus may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

The phosphine oxide or phosphine sulphide substituent may have phenyl or substituted phenyl groups R on the phosphorus.

Thus substituents:

 and , or substituents where one or both phenyl groups are substituted, are contemplated for donor moieties D.

Thus TADF compound according to the fourth aspect the present invention may be according to formula Id:

Id

wherein the ring II:

II

represents an aromatic spacer ring wherein each Acc is an acceptor moiety with each acceptor moiety Acc bonded to adjacent carbon atoms, each D is a donor moiety and each donor moiety D bonded to adjacent carbon atoms, and

27

wherein the donor moieties D are independently selected from the group consisting of formula A and formula B :

A

B

wherein −L represents the bonding position to ring II;

X^1 is selected from the group consisting of O, S, NR, SiR_2, PR and CR_2, wherein each R is independently selected from the group consisting of −H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10); and

 represents, independently for each occurrence a substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A or B, for example a five or a six membered substituted or unsubstituted aryl or heteroaryl ring; and wherein

at least one substituent on at least one present in the compound is phosphine oxide or phosphine sulphide.

Brief Description of the Drawings

Figure 1 shows cyclic voltammetry studies of compounds of the invention; and

Figure 2 shows the structure of OLEDs in schematic cross section.

Detailed Description of Some Embodiments and Experimental Results

General Synthetic Procedures

All the commercially available chemicals and reagent grade solvents were used as received. Air-sensitive reactions were performed under a nitrogen atmosphere using Schlenk techniques.   Flash column chromatography was carried out using silica gel (Silia-P from Silicycle, 60 Å, 40-63 μm). Analytical thin-layer-chromatography (TLC) was performed with silica plates with aluminum backings (250 μm with F-254 indicator). TLC visualization was accomplished by 254/365 nm UV lamp. ^1H, ^{13}C and ^{19}F NMR

28

spectra were recorded on a Bruker Advance spectrometer. Melting points were measured using open-ended capillaries on an Electrothermal melting point apparatus and were uncorrected. High-resolution mass spectrometry (HRMS) was performed by EPSRC National Mass Spectrometry Service Centre (NMSSC), Swansea.

Synthesis of TADF emitters with heterocyclic acceptor moieties

Prior art TADF compound "2CzPN":

The synthesis was largely adopted from literature. (reference 4) To a solution of carbazole (2.0 g, 12.0 mmol, 1 equiv.) in dry THF (40 mL) at room temperature was portionwise added sodium hydride (60% in mineral oil, 0.96 g, 24.0 mmol, 2 equiv.). The suspension was stirred under nitrogen protection for 15 minutes. 4,5-difluorophthalonitrile (1.2 g, 0.72 mmol, 0.6 equiv.) was added. The colour of the suspension changed from milky to red immediately and it was allowed to stir for further 3 h. Green emission (upon excitation with 365 nm UV light) slowly developed during the course of the reaction. The suspension was then slowly added to ice water and then the mixture was extracted with DCM (3 x 25 mL). The combined organic layers were dried with anhydrous sodium sulfate and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography using DCM : Hexanes = 3 : 2 as eluent to afford the title compound. Green solid. **Yield**: 74%. R_f: 0.39 (EtOAc : Hexanes = 1:4 on silica). **Mp**: 332-333°C. **^{1}H NMR (300 MHz, CDCl$_3$) δ (ppm)**: 8.33 (s, 2 H), 7.82-7.79 (m, 4 H), 7.16-7.06 (m, 12 H). **^{13}C NMR (76 MHz, CDCl$_3$) δ (ppm)**: 138.4, 138.2, 135.5, 126.2, 124.3, 121.7, 120.4, 114.7, 114.5, 109.0.

The following three compounds, IV, V, VI were prepared from 2CzPN.

General procedures for synthesis of **IV, V, VI**.

5   **2CzPN** (120 mg, 0.26 mmol, 1.0 equiv.), ammonium chloride (84 mg, 1.56 mmol, 6.0

equiv.) and sodium azide (100 mg, 1.56 mmol, 6.0 equiv.) were mixed in DMF (2.5 mL)

and heated at 110 °C for 8 h. After cooling, the reaction mixture was poured into water

to afford a grey solid, which was dried and used directly without purification. The solid

was then dissolved in dry pyridine (2 mL) and the appropriate acid chloride was added

10   dropwise over 10 seconds. The reaction mixture was heated at 110 °C for 6 h. After

cooling, the mixture was added to 10% HCl (10 mL). The mixture was then extracted

with DCM (3 x 10 mL). The combined organic layer was dried with anhydrous sodium

sulfate and concentrated under reduced pressure. The crude mixture was purified by

flash column chromatography with ethyl acetate/hexanes as eluent.

15   **IV:**

White solid. **Yield:** 64%. **Mp:** Decompose. **R$_f$:** 0.25 (EA : Hexanes = 3:2, silica). **^{1}H**

NMR (300 MHz, CD$_2$Cl$_2$) δ (ppm): 8.47 (s, 2 H), 7.90-7.86 (m, 4 H), 7.30-7.26 (m, 4 H),

7.15-7.11 (m, 8 H), 2.61 (s, 6 H). ^{13}C **NMR (76 MHz, CD$_2$Cl$_2$) δ (ppm)**: 165.5, 163.1, 139.9, 137.5, 133.3, 126.7, 124.6, 121.5, 120.8, 110.3, 11.7. **HR-MS (ESI): [M+H]$^+$ Calculated**: (C$_{36}$H$_{25}$N$_6$O$_2$) 573.2034; **Found**: 573.2028.

IV:

Tan solid. **Yield**: 70%. **Mp**: 309-310 °C. **R$_f$**: 0.25 (EA : Hexanes = 1:3, silica). ^{1}H **NMR (400 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.68 (s, 2 H), 8.05-8.03 (m, 4 H), 7.92-7.90 (m, 4 H), 7.58-7.56 (m, 2 H), 7.52-7.48 (m, 4 H), 7.36-7.34 (m, 4 H), 7.20-7.16 (m, 8 H). ^{13}C **NMR (101 MHz, CD$_2$Cl$_2$) δ (ppm)**: 165.6, 162.2, 139.2, 137.1, 132.7, 132.1, 129.2, 126.9, 125.9, 123.9, 123.6, 123.4, 120.8, 120.1, 109.6. **HR-MS: [M+H]$^+$ Calculated**: (C$_{46}$H$_{29}$N$_6$O$_2$) 697.2347; **Found**: 697.2347.

VI:

Tan solid. **Yield**: 71%. **Mp**: 179-180 °C. **R$_f$**: 0.50 (EA : Hexanes = 1:3, silica). ^{1}H **NMR (400 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.69 (s, 2 H), 8.20 (d, J = 8.4 Hz, 4 H), 7.93-7.91 (m, 4 H), 7.79 (d, J = 8.4 Hz, 4 H), 7.36-7.33 (m, 4 H), 7.19-7.17 (m, 8 H). ^{13}C **NMR (101 MHz, CD$_2$Cl$_2$) δ (ppm)**: 164.4, 162.6, 139.1, 137.3, 132.9, 127.4, 126.2, 126.2, 126.0, 123.9, 123.3, 120.9, 120.1, 109.5. ^{19}F {^{1}H} **NMR (376 MHz, CD$_2$Cl$_2$) δ (ppm)**: -63.6. **HR-MS (ESI) [M+H]$^+$ Calculated**: (C$_{48}$H$_{27}$F$_6$N$_6$O$_2$) 833.2094; **Found**: 833.2104.

Photophysical measurements.

Optically dilute solutions of concentrations on the order of 10^{-5} or 10^{-6} M were prepared in HPLC grade solvent for absorption and emission analysis. Absorption spectra were recorded at room temperature on a Shimadzu UV-1800 double beam

5   spectrophotometer with a 1cm quartz cuvette. Molar absorptivity values were determined from at least four solutions followed by linear regression analysis.

For emission studies, aerated solutions were bubbled by compressed air for 5 minutes and spectra were taken using the cuvette for absorption analysis. Degassed solutions were prepared via five freeze-pump-thaw cycles and spectra were taken using home-

10   made Schlenk quartz cuvette. Steady state emission, excitation spectra and time-resolved emission spectra were recorded at 298 K using an Edinburgh Instruments F980. Samples were excited at 360 nm for steady state measurements while at 378 nm for time-resolved measurements and 450 nm was monitored for excitation spectra. Photoluminescence quantum yields for solutions were determined using the optically

15   dilute method (Reference 5) in which four sample solutions with absorbances of ca. 0.10, 0.080, 0.060 and 0.040 at 360 nm were used. The Beer-Lambert law was assumed to remain linear at the concentrations of the solutions. For each sample, linearity between absorption and emission intensity was verified through linear regression analysis with the Pearson regression factor (R^2) for the linear fit of the data

20   set surpassing 0.9. Individual relative quantum yield values were calculated for each solution and the values reported represent the slope obtained from the linear fit of these results. The equation $\Phi_s = \Phi_r(A_r/A_s)((I_s/I_r)(n_s/n_r)^2$ was used to calculate the relative quantum yield of the sample, where (Φ_r) is the absolute quantum yield of the external reference quinine sulfate ($\Phi_r = 54.6\%$ in 1 N H$_2$SO$_4$),(Reference 6). A stands

25   for the absorbance at the excitation wavelength, I is the integrated area under the corrected emission curve and n is the refractive index of the solvent. The subscripts "s" and "r" representing sample and reference, respectively. The experimental uncertainty

32

in the emission quantum yields is conservatively estimated to be 10%, though we have found that statistically we can reproduce PLQYs to 3% relative error. An Integrating sphere was employed for quantum yield measurements for thin film samples.

5   Electrochemistry measurements.

Cyclic Voltammetry (CV) analysis was performed on an Electrochemical Analyzer potentiostat model 600D from CH Instruments. Samples were prepared as MeCN solutions, which were degassed by sparging with MeCN-saturated argon gas for 15 minutes prior to measurements. All measurements were performed using 0.1 M MeCN

10   solution of tetra-n-butylammonium hexafluorophosphate. An Ag/Ag$^+$ electrode was used as the reference electrode while a platinum electrode and a platinum wire were used as the working electrode and counter electrode, respectively. The redox potentials are reported relative to a saturated calomel electrode (SCE) with a ferrocenium/ferrocene (Fc$^+$/Fc) redox couple as the internal standard (0.38 V vs SCE).

15

OLED fabrication and characterization.

A pre-patterned ITO glass substrate (Figure 2) was treated by ultrasonic cleaning in acetone and propan-2-ol consecutively and then being treated by oxygen plasma. A PEDOT:PSS layer was spin-coated on the ITO substrate and subsequently baked at

20   120 °C for 10 minutes inside the glove-box to remove the residual moisture. Around 30 nm thick layer of PVK, acting as the hole-transporter, was spin-coated from a chlorobenzene solution and then baked at 120 °C for another 10 minutes. After spin-coating the emitting layer onto PVK, the sample was transferred into the vacuum chamber. A layer of electron-transporting material, B3PYMPM, was thermally

25   deposited. Finally, Ca/Al as the composite cathode was thermally deposited through a shadow mask in the vacuum chamber under a pressure of ~2.0 × 10^{-6} mbar. All the devices were encapsulated with UV epoxy resin inside the glove-box. The luminance-

33

current-voltage characteristics were measured in ambient environment using Keithley

2400 source meter and a 2000 multi-meter connected to a calibrated Si photodiode.

The external quantum efficiency was calculated with the assumption of a Lambertian

distribution. The electroluminence spectrum was captured by an Andor DV420-BV

5   CCD spectrometer.

Results and Discussion
Synthesis

Scheme 1. Synthesis of **IV, V and VI**.

10

The synthetic route for **IV, V and VI** is shown in Scheme **1**.

Despite the many synthetic routes available for the installation of the oxadiazole motif,

(Reference 7) a two-step protocol, passing through a tetrazole intermediate is the most

15   straightforward (Reference 4), given the presence of the cyano groups in the known

2CzPN. Thus, **2CzPN** was reacted with ammonium chloride and NaN$_3$ in DMF at 110

°C to give the tetrazole intermediates, which were subsequently directly reacted with

34

corresponding acid chlorides to provide the desired oxadiazole emitters in good yield

(64-71%).

Absorption and Electrochemistry

5   **Table 1**. Summary of absorption and electrochemistry of **IV**, **V and VI** and **2CzPN** as

control.

Compound	$\lambda_{abs}{}^{a}$ (nm), [ε ($\times 10^4$ M^{-1} cm^{-1})]	Electrochemistry[b] (eV)
IV	281 [2.26], 290 [2.46], 321 [1.37], 335 [1.51], 353 [1.36]	HOMO: -5.83 LUMO: -2.70 ΔE: 3.13
V	258 [5.38], 283 [4.39], 291 [4.48], 320 [2.38], 333 [2.20], 361 [2.12]	HOMO: -5.84 LUMO: -2.80 ΔE: 3.04
VI	257 [4.81], 283 [4.36], 291 [445], 319 [2.00], 332 [1.95], 367 [1.79]	HOMO: -5.84 LUMO: -2.86 ΔE: 2.98
2CzPN		HOMO: -5.84 LUMO: -2.99 ΔE: 2.85

[a] in DCM at 298 K. [b] in MeCN with 0.1 M [nBu$_4$N]PF$_6$ as the supporting electrolyte and Fc/Fc$^+$ as the internal reference. The HOMO and LUMO energies were calculated using the relation $E_{HOMO/LUMO} = -(E^{ox}_{pa,1}/ E^{re}_{pc,1} + 4.8)$eV, where E^{ox}_{pa} and E^{red}_{pc} are anodic and cathodic peak potentials respectively. ΔE = -(E_{HOMO}-E_{LUMO}).

The electrochemistry of IV, V and VI was studied by CV in degassed MeCN solutions

10   under argon, Figure **1**. The HOMO levels of the dyes are practically identical (-5.83 to -

5.84 eV) because they have the same carbazole donor. Yet, their LUMO levels are

strongly influenced by the acceptor strength induced by the groups attached to the

oxadiazole. The LUMO level of **V** is lower by 0.1 eV compared to **IV** as a result of

increased conjugation length afforded by the phenyl group. Emitter **VI** has the most

15   stabilized LUMO (-2.86 eV) due to the strong electron-withdrawing effect of the

trifluoromethyl group. The oxidations of all three dyes are irreversible, which is not

35

unexpected as carbazole radical cations are known to be electrochemically unstable and undergo dimerization. Only **3** shows an irreversible reduction, probably due to cleavage of the C-F bond following reduction. breakage of carbon-fluorine bond after being reduced.

Photophysics

Table 2 (below) shows a summary of photo physics measurements.

Table **2.** Summary of solution and thin film photophysical properties of **IV, V and VI**

	Solution Photophysics							
	$\lambda_{em}{}^{a}$ (nm)			$\Phi_{PL}{}^{b}$ (%)			τ_e (ns)	
	PhMe	DCM	ACN	PhMe	DCM	ACN	PhMe	ACN
IV	448 (76)	487 (98)	505 (113)	24.5 (28.7)	26.3 (35.3)	15.5 (28.6)	15.1,1310 (1.1)	25.0, 1180 (0.9)
V	466 (80)	502 (105)	531 (125)	27.5 (38.3)	29.7 (29.9)	14.5 (27.3)	15.4, 1270 (1.0)	22.6, 556 (1.3)
VI	484 (88)	518 (111)	542 (136)	25.7 (39.1)	27.9 (31.4)	12.4 (18.8)	13.2, 1310 (1.7)	17.7, 797 (1.5)
2Cz PN	478 (88)			7.9 (22.6)			33.0, 14,946	

36

	λ_{em} (nm)	$\Phi_{PL}{}^{d}$ (%)	τ_e (ns)
		Table 2 continued	
		Thin Film Photophysics^c	
IV	429 (69)	39.6 (46.4)	12,1900
V	442 (73)	54.5 (62.0)	11,1582
VI	464 (82)	57.1 (74.9)	12,1989

$^{a.}$ Emission maxima and full-width at half maximum (FWHM) are reported from degassed solutions. FWHM in parentheses. $^{b.}$ 0.5M quinine sufhate in H_2SO_4 (aq) was used as reference (PLQY: 54.6%).[10] Vallues quoted are in aerated solutions, which were prepared by bubbling with air for 5 minutes. Values in parentheses are for degassed solutions, which were prepared by five s freeze-pump-thaw cycles. $^{c.}$ Thin films were prepared by spin-coating doped samples in PMMA (10% w/w). $^{d.}$ Determined using an integrating sphere.

The solution-state photophysical properties of **IV, V and VI** were studied in toluene, DCM and MeCN. All the three TADF emitters show positive solvatochromism and broad and unstructured emission profiles, which are characteristic of ICT emitters. The broadness of emission, which is characterized by full width at half maximum (FWHM), also increases with increasing polarity of the solvent. Regardless of solvent, the emission maxima increase in the order: **IV** < **V** < **VI**, which is consistent with the bandgaps obtained from electrochemistry.

The photoluminescence quantum yields (Φ_{PL}) range from 12-39% and do not significantly change with solvent choice. The quantum yields in degassed solutions are

always higher than those in aerated solutions, which suggests that there is a contribution from the triplet excited state towards emission, a typical observation of TADF materials. The emission lifetimes (τ_e) of **IV, V, VI** consist of both prompt (13.2-25.0 ns) and delayed (556-1310 ns) components, which are characteristic of TADF

5   emission .

The weaker acceptor strength of oxadiazole compared to the cyano group causes a desired blue-shifted emission in emitters **IV, V, VI** compared with **2CzPN**. Indeed, the LUMO levels of **IV, V, VI** range from -2.70 eV to -2.86 eV while the LUMO of **2CzPN**

10   was found to be -2.99 eV, and the emission is blue-shifted as a consequence. For example, **IV** has an emission maximum at 448 nm in toluene, blue-shifted by 30 nm compared with **2CzPN** (478 nm) in the same solvent. In addition, the emission lifetimes of delayed components for **1-3** range from 0.5 to 1.3 µs, which are significantly shorter than that observed for **2CzPN** (14.9 µs). The short delayed component of the emission

15   lifetimes reveal a smaller singlet-triplet energy gap, which is a consequence of greater electronic separation between donor (HOMO) and acceptor (LUMO) units in **IV, V,** and **VI** compared with **2CzPN**. The delayed component emission lifetimes **of IV, V** and **VI** are among the shortest of the organic TADF materials known.

20   For thin film measurements, high quality thin films were prepared by spin-coating DCM solution of 10 wt% dye in PMMA. All the emission maxima are blue-shifted by ~20 nm and the profiles slightly sharper compared with those measured in toluene solution. The thin film quantum yields (40-75%) are significantly higher than in solution as a result of the more rigid environment. In particular, **V** (λ_{em}: 442 nm) and **VI** (λ_{em}: 464 nm)

25   exhibit remarkable quantum yields of 62% and 75% in the deep-blue region under nitrogen, making them useul blue TADF materials for OLED applications. Similar to

38

their behaviour in solution, the quantum yields of the thin films are higher under a nitrogen atmosphere than when exposed to air, suggesting the presence of TADF in solid state. The emission lifetimes (τ_e) of **IV, V, VI** in thin film consist of both prompt (11-12 ns) and delayed (1582-1989 ns) components, which are characteristic of TADF

5   emission.

Electroluminescence Performances.

A series of OLEDs based on the three emitters were fabricated with the multi-layer architecture shown in Figure **2**, where PVK, mCP and OXD-7 were used as the hole

10   transporting layer (HTL), electron blocking layer and the exciton blocking layer (EBL), respectively while B3PYMPM was used as the electron transporting layer (ETL) layer. Ca was used to reduce the injection barrier. This multi-layer structure provides a compact emissive layer (EML) where the excitons were finely confined to enhance radiative recombination rate.

15

Nine devices were constructed to compare the properties of the emitters, i.e. for the emissive layer,

A1: mCP:OXD-7:**IV** (70:20:10), **A2**: mCP: **IV** (90:10), **A3**: **IV**(without additives);

20   **B1**: mCP:OXD-7:**V** (70:20:10), **B2**: mCP: **V** (90:10), **B3**: **V**;

C1: mCP:OXD-7:**VI** (70:20:10), **C2**: mCP: **VI** (90:10), and **C3**: **VI**, respectively.

(PEDOT:PSS = poly(3,4-ethylenedioxythiophene): poly(styrenesulfonate), PVK =

25   poly(*N*-vinylcarbazole), mCP = 3,5'-*N,N*-dicarbazole-benzene, OXD-7 = 1,3-bis[(4-*tert*-butylphenyl)-1,3,4-oxadiazolyl]   phenylene,   B3PYMPM   =   bis-4,6-(3,5-di-3-pyridylphenyl)-2-methylpyrimidine)

39

A summary of photo physics results for these OLEDs is given in Table 3 below.

Table **3**. Comparison of the performance of the devices

Device	V_{on}[a]	λ_{peak}[b]	FWHM[c]	$EQE_{max.}$[d]	CE_{max}[e]	$PE_{max.}$[f]	CIE[g]
	(V)	(nm)	(nm)	(%)	(cd/A)	(lm/W)	
A1	7.4	455	131	0.56	0.98	0.30	(0.23, 0.27)
A2	7.3	462	120	0.73	1.22	0.41	(0.23, 0.26)
A3	10.9	544	175	0.04	0.09	0.02	(0.34, 0.42)
B1	6.0	466	106	1.00	1.84	0.79	(0.21, 0.28)
B2	6.5	471	104	1.04	1.95	0.77	(0.22, 0.29)
B3	9.3	573	163	0.24	0.61	0.17	(0.40, 0.46)
C1	7.5	501	125	1.43	3.45	1.32	(0.29, 0.40)
C2	7.1	497	123	2.00	4.81	2.14	(0.27, 0.40)
C3	8.0	581	142	0.13	0.34	0.11	(0.44, 0.49)

[a] V_{on} -Turn-on voltage @1 cd/m^2. [b] λ_{peak} -Peak wavelength at 1 mA/cm^2. [c] FWHM - Full width at half maximum of the EL spectrum at 1 mA/cm^2. [d] EQE_{max}-Maximum external quantum efficiency. [e] CE_{max} -Maximum current efficiency. [f] PE_{max} -Maximium power efficiency [g] CIE -The Commission Internationale de L'Eclairage coordinates at 1 mA/cm^2.

Cruciform TADF Structures Having Different Donor Moieties D

Scheme 2 (below) shows the synthetic route to TADF structures employing different nitrogen containing donor moieties D. The route is similar to that of Scheme 1 for compounds 2CzPN, VIII and IX, with minor differences.

To a solution of corresponding nitrogen donor moiety (2 equiv.) in dry THF (20 mL) was added portionwise NaH (60% in mineral oil, 4 equiv.) and the mixture was stirred for 15 mins. 4,5-difluorophthalonitrile (1 equiv.) was added and the mixture was allowed to stir for further 3 h. The mixture was slowly added to ice-water (20 mL) and extracted with DCM (20 mL x 3). The combined organic phase was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column

40

chromatograph using DCM:Hexanes (v/v = 1:1) as the eluent. The solid obtained was further recrystallized from DCM/Hexanes (v/v = 1:9) to afford the analytically pure final product.

5   Compound X is made in a two stage process from difluorophthalonitrile via carbazole intermediate XII CzFPN, which is itself a TADF emitter material. Also shown in Scheme 2 is the synthesis of the 3-bromocarbazole derivative XI (3-BrCz)2PN:

XI

(3-BrCz)₂PN   This compound illustrates substitution on the aromatic rings

10   of a donor moiety D.

D=	carbazole		2CzPN,	71%
	phenoxazine	VIII	(PXZ)₂PN,	75%
	phenothiazine	IX	(PTZ)₂PN,	66%
	3-bromocarbazole	XI	(3-BrCz)₂PN,	75%

Scheme 2: synthesis of VIII, IX, X, intermediate XII and 3-bromocarbazole variant XI

15

41

CzFPN, XII:

XII was prepared in the same way as **2CzPN** except that 1 equiv. of carbazole was used. Light yellow solid. **Yield**: 81%. **R$_f$**: 0.42 (EtOAc : Hexanes = 1:4 on silica). **Mp**: 225-226 °C. ^{1}**H NMR (300 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.19-8.17 (m, 3 H), 7.90 (d, J = 9.2, 1 H), 7.51 (td, $J$ = 7.7, 1.2 Hz, 2 H), 7.41 (td, J = 7.5, 1.0 Hz, 2 H), 7.27 (dd, J = 8.2, 2.5 Hz, 2 H), ^{13}**C NMR (76 MHz, CD$_2$Cl$_2$) δ (ppm)**: 162.0, 158.4, 140.3, 135.4, 135.4, 131.9, 131.7, 127.5, 125.1, 124.4, 124.1, 122.6, 121.4, 116.7, 116.5, 115.0, 114.4, 114.4, 110.5, 110.4. ^{19}**F NMR (282 MHz, CD$_2$Cl$_2$) δ (ppm)**: 105.0. **Anal. Calcd. for C$_{20}$H$_{10}$FN$_3$**: C, 77.16%; H, 3.24%; N, 13.50%. Found: C, 77.14%; H, 3.16%; N, 13.41%. **HR-MS (ESI) [M+NH$_4$]$^+$ Calculated**: (C$_{20}$H$_{14}$FN$_4$) 329.1197; **Found**: 329.1200.

(3-BrCz)$_2$PN, XI:

Light Green solid. **Yield**: 75%. **R$_f$**: 0.39 (EtOAc : Hexanes = 1:4 on silica). **Mp**: 315-316 °C. ^{1}**H NMR (300 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.35 (s, 1 H), 8.35 (s, 1 H), 7.94 (dd, J = 6.5, 1.7 Hz, 2 H), 7.87-7.82 (m, 2 H), 7.27-7.10 (m, 8 H), 6.99 (d, J = 8.7, 1 H), 6.91 (d, J = 8.7, 1 H). ^{13}**C NMR (76 MHz, CD$_2$Cl$_2$) δ (ppm)**: 139.5, 139.5, 138.6, 137.8, 137.7, 136.3, 129.6, 129.4, 128.0, 127.8, 126.8, 126.7, 124.1, 124.0, 123.9, 123.8, 122.9, 122.8, 121.5, 121.4, 116.2, 115.2, 115.2, 115.1, 111.4, 111.3, 111.1, 109.9. **Anal. Calcd. for C$_{32}$H$_{16}$N$_4$Br$_2$**: C, 62.36%; H, 2.62%; N, 9.09%. Found: C, 62.26%; H, 2.52%; N, 8.95%. **HR-MS (ESI) [M+NH$_4$]$^+$ Calculated**: (C$_{32}$H$_{20}$N$_5$Br$_2$) 634.0062; **Found**: 634.0059.

25

42

(PXZ)₂PN VIII:

Crimson solid. **Yield**: 58%. **R$_f$**: 0.46 (EtOAc : Hexanes = 1:4 on silica). **Mp**: 375-376 °C. **¹H NMR (300 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.18 (s, 2 H), 6.65 (td, J = 7.2, 1.4 Hz, 4 H), 6.57 (dd, J = 8.0, 1.7 Hz, 4 H), 6.40 (td, J = 8.0, 1.7 Hz, 4 H), 6.06 (dd, J = 8.0, 1.4 Hz, 4 H), **¹³C NMR (76 MHz, CD$_2$Cl$_2$) δ (ppm)**: 145.7, 143.8, 140.9, 131.3, 124.2, 123.5, 116.9, 116.3, 115.3, 114.8. **Anal. Calcd. for C$_{32}$H$_{18}$N$_4$O$_2$**: C, 78.36; H, 3.70; N, 11.42 Found N/A. **HR-MS (ESI) [M+Na]⁺ Calculated**: (C$_{32}$H$_{18}$N$_4$O$_2$Na) 513.1322; **Found**: 513.1314.

(PTZ)₂PN, IX:

Red solid. **Yield**: 66%. **R$_f$**: 0.43 (EtOAc : Hexanes = 1:4 on silica). **Mp**: 339-340°C. **¹H NMR (400 MHz, CDCl$_3$) δ (ppm)**: 7.80 (s, 2 H), 7.26-6.92 (m, 4 H), 6.81-6.79 (m, 12 H), 6.32-6.30 (m, 4 H). **¹³C NMR (100 MHz, CDCl$_3$) δ (ppm)**: 143.9, 140.7, 137.1, 127.3, 126.9, 125.3, 124.3, 118.8, 114.6, 114.1. **Anal. Calcd. for C$_{32}$H$_{18}$N$_4$S$_2$**: C, 73.54%; H, 3.47%; N, 10.72%. Found: C, 73.39%; H, 3.45%; N, 10.63%. **HR-MS (ESI) [M+H]⁺ Calculated**: (C$_{32}$H$_{19}$N$_4$S$_2$) 523.1046; **Found**: 523.1032.

CzPTZPN, X:

To a solution of phenothiazine (31.8 mg, 0.16 mmol, 1 equiv.) in dry THF (5 mL) was added portionwise NaH (60% in mineral oil, 25.6 mg, 0.32 mmol, 2 equiv.). The mixture was stirred for 15 mins. Compound **2** (50 mg, 0.16 mmol, 1 equiv.) was added and the mixture was allowed to stir for further 3 h. The mixture was slowly added to ice-water (10 mL) and extracted with DCM (10 mL x 3). The combined organic phase was dried

43

by anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatograph using DCM:Hexanes (*v/v* = 1:1) as the eluent. The solid obtained was further recrystallized from DCM/Hexanes mixture to afford the final product. Tan solid. **Yield**: 64%. **R$_f$**: 0.46 (EtOAc : Hexanes = 1:4 on silica). **Mp**:

5   316-317 °C. **^{1}H NMR (300 MHz, CD$_2$Cl$_2$) δ (ppm)**: 8.27 (s, 1 H), 8.12 (s, 1 H), 8.00-7.97 (m, 2 H), 7.20 (td, *J* = 7.2, 1.1 Hz, 1 H), 7.13-7.07 (m, 2 H), 6.89-6.82 (m, 3 H), 6.80-6.75 (m, 5 H), 6.57 (t, *J* = 0.8 Hz, 1 H), 6.55 (q, *J* = 0.5 Hz, 1 H). **^{13}C NMR (76 MHz, CD$_2$Cl$_2$) δ (ppm)**: 145.5, 141.3, 140.1, 140.0, 137.8, 137.5, 127.1, 126.8, 125.7, 125.5, 124.3, 124.0, 120.8, 120.1, 117.6, 116.0, 114.8, 114.7, 114.5, 109.5. **Anal.**

10   **Calcd. for C$_{32}$H$_{18}$N$_4$S**: C, 78.35%; H, 3.70%; N, 11.42%. Found: C, 78.37%; H, 3.71%; N, 11.41%. **HR-MS** (ESI) **[M+NH$_4$]$^+$ Calculated**: (C$_{32}$H$_{22}$N$_5$S) 508.1590; **Found**: 508.1572.

Absorption and Electrochemistry

15   Table 4 lists in Summary the absorption and electrochemistry data for compounds VIII, IX, X, XI, XII and 2CzPN.

Table 4

Compound	λ$_{abs}$^{a} (nm), [ε (×10^4 M^{-1} cm^{-1})]	HOMO^b (eV)	LUMO^b (eV)	ΔE^b (eV)
2CzPN	280(sh) [1.72], 289 [2.14], 319 [1.02], 329 [1.17], 364 [1.14]	-5.88	-2.97	2.91
XII	277(sh) [1.07], 286 [1.28], 316 [0.49], 331 [0.68], 348 [0.72]	-5.95	-2.89	3.06
XI	261 (sh) [2.56], 285 (sh) [1.73], 294 [2.20], 326 [1.15], 340 [1.23], 362 [1.24]	-6.00	-3.01	2.99
VIII	309 [0.87], 373(sh) [0.18], 443 [0.30]	-5.27	-2.99	2.28
IX	297 [0.64], 313 [0.63], 424 [0.15]	-5.15	-2.98	2.17
X	283 [1.55], 318 [0.84], 330 [0.77], 372 [0.52]	-5.29	-3.01	2.28

^{a} in MeCN at 298 K. ^{b} in MeCN with 0.1 M [*n*Bu$_4$N]PF$_6$ as the supporting electrolyte

and Fc/Fc$^+$ as the internal reference. The HOMO and LUMO energies were calculated using the relation $E_{HOMO}/_{LUMO} = -(E^{ox}_{pa,1}/ E^{red}_{pc,1}+ 4.8)eV$, where E^{ox}_{pa} and E^{red}_{pc} are anodic and cathodic peak potentials, respectively. $\Delta E = -(E_{HOMO}-E_{LUMO})$.

Photophysics

Table 5 (below) shows a summary of photo physics measurements.

Summary of solution and thin film photophysical data of compounds compounds VIII, IX, X, XI, XII and 2CzPN.

Table 5

Emitter	In Toluene			Doped Film^c		
	$\lambda_{em}{}^a$ (nm)	$\Phi_{PL}{}^b$ (%)	τ_e (ns)	$\lambda_{em}{}^a$ (nm)	$\Phi_{PL}{}^d$ (%)	τ_e (ns)
2CzPN	478	22.6 (7.9)	33.0, 14900	492	76.0 (62.6)	18.4, 19700
XII	451	25.3 (8.5)	13.0, 501	460	61.4 (57.7)	11.0, 22000
XI	470	2.9 (2.2)	3.5, 12100	478	52.0 (34.0)	2.3, 22200
VIII	650	3.6 (1.1)	5.0, 445	616	5.9 (5.6)	6.6, 670
IX	674	1.8 (0.3)	13.1, 776	622	3.9 (3.6)	8.6, 540
X	656	2.2 (1.3)	3.9, 279	600	5.8 (5.6)	9.5, 1000

[a] Emission maxima are reported from degassed solutions. [b] 0.5 M quinine sulfate in H_2SO_4 (aq) was used as reference (PLQY: 54.6%).[12] Values quoted are in degassed solutions. Values in parentheses are for aerated solutions. [c] Thin films were prepared by spin-coating doped samples in PMMA (10% w/w). [d] Values determined using an integrating sphere. Degassing was done by N_2 purge.

In the normalised emission spectra (see figure 3) compounds possessing only carbazole as the donor (compounds XI, XII and 2CzPN.) are strongly emissive in the blue to sky-blue region of the visible spectrum. Compounds possessing the much

45

stronger PTZ (phenothiazine) and PXZ (phenoxazine) donors (VIII, IX, X) are red emissive. Compound XII shows the bluest emission of the family with an emission that is blue-shifted by 27 nm compared with the reference 2CzPN. The addition of the electron-withdrawing bromine onto the carbazole in XI likewise induces a small blue-shift of 8 nm in the emission. By contrast, phenothiazine was found to act as the strongest donor with an emission maximum in IX of 674 nm and phenoxazine promoted a smaller red-shift with an emission maximum found at 650 nm in VIII. Interestingly, the emission profile for **X** is blue-shifted by 18 nm compared to **VIII**, pointing to a HOMO in **X** localized on the PTZ ring but whose energy is modulated by the carbazole, most likely via π-stacking interactions.

The decay profiles of all the compounds show prompt and delayed components in degassed toluene and doped thin films, indicating TADF materials. The lifetimes of 2CzPN and **XI** are similar because of their similar structures. For compounds VIII, IX and X, the delayed components are much shorter (279-1000 ns) compared with 2CzPN.

OLED devices

OLED devices for compounds VIII, IX, X, XI, XII and 2CzPN were fabricated with the same device architecture as shown in figure 2 with the emissive layer comprising mCP:OXD-7:Emitter material (70:20:10, 20 nm thickness).

Results summarising the Electroluminescence (EL) spectra are shown in Table 6. The breadth of emission spectrum is suggested by the FWHM values (full-width at half-maximum)

Table **6** Comparison of the performance of the six devices.

Compound	$V_{on}(V)$ [a] @1 cd/m²	λ_{max} (nm) [b]	FWHM (nm)	EQE_{max} (%) [c]	CIE [d]
2CzPN	4.8	508	109	4.64	(0.26, 0.46)
XII	6.1	526	152	0.96	(0.30, 0.42)
XI	5.5	507	123	3.67	(0.29, 0.46)

46

|					
VIII	7.0	618	117	1.47	(0.56, 0.42)
IX	7.6	629	122	0.65	(0.60, 0.39)
X	6.2	617	119	1.90	(0.58, 0.42)

[a.] Turn-on voltage. [b.] Peak emission at 1 mA/cm^2. [c.] Maximum external quantum efficiency. [d.] CIE at 1 mA/cm^2.

For the emitters with the donor units changing from carbazole to phenoxazine (**VIII**) or phenothiazine (**IX** and **X**), the emission color significantly shifts from bluish-green to deep-red, e.g., peak wavelength of 629 nm and CIE coordinates of (0.60, 0.39) for the emitter **VIII**. Tests at different current densities show that the compounds with phenoxazine and phenothiazine donors, as well as brominated carbazole donors, show extremely stable EL spectra, which are independent of the current density applied. This is in contrast with carbazole containing compounds where peak wavelength was found to shift depending on current density applied.

Synthesis of TADF compounds having donor moieties modified with phosphine oxide or phosphine sulphide substituents

The general synthetic route is shown in Scheme 2 below. The method is illustrated by preparing TADF compounds having carbazole derived donor moieties D with cyano acceptor moieties A.

47

Scheme 2

Experimental details for compounds 1 to 8 in Scheme 2.

Preparation of N-tert-butyldimethylsilyl-3-bromocarbazole, 1:

48

This was prepared by the known method (Chem. Mater., 2015, 27, 6535-6542).

Preparation of 3-(diphenylphosphoryl)carbazole, 2:

To a solution of **1** (500 mg, 1.4 mmol, 1.0 equiv.) in dry THF (10 mL) cooled at -78 °C was added dropwise 1.6 M *n*-BuLi solution (1.1 mL, 1.7 mmol, 1.2 equiv.). The reaction mixture was stirred at this temperature for 15 min. Chlorodiphenylphosphine (0.30 mL, 1.7 mmol, 1.2 equiv.) was added and the mixture was raised to room temperature, followed by stirring for 1 h. 30% H_2O_2 (0.6 mL, 5.1 mmol, 3.0 equiv.) was added and the mixture was stirred for 30 min. Finally, *n*-tetrabutylammonium fluoride (1.34 g, 5.1 mmol, 3.0 equiv.) was added and the mixture was allowed to stir for further 30 min. The mixture was added to water (10 mL) and extracted by DCM (3x 10 mL). The combined organic layer was dried with anhydrous sodium sulphate. The concentrated organic layer was purified by column chromatography using EA/Hexanes (*v/v* 2:1) as the eluent. White solid. **Yield**: 71%. **Mp**: 310 °C. **R$_f$**: 0.34 (EA, silica). **^{1}H NMR (300 MHz, DMSO-*d6*) δ (ppm)**: 11.73 (s, 1 H), 8.49 (d, *J* = 14.1 Hz, 1 H), 8.10 (d, *J* = 7.8 Hz, 1 H), 7.73-7.50 (m, 13 H), 7.43 (td, *J* = 7.7, 1.1 Hz, 1 H), 7.18 (td, *J* = 7.5, 0.9 Hz, 1 H), ^{13}C **NMR (76 MHz, DMSO-*d6*) δ (ppm)**: 141.9, 141.9, 140.7, 134.6, 133.5, 132.3, 132.1, 132.1, 132.0, 129.3, 129.1, 129.1, 127.0, 125.2, 125.1, 122.9, 122.7, 122.3, 121.3, 121.0, 120.1, 120.0, 111.9, 111.7, 111.6. ^{31}P **NMR (121 MHz, DMSO-*d6*) δ (ppm)**: 43.24. **HR-MS (ESI)**: **[M + H]$^+$ Calculated**: ($C_{24}H_{19}NOP$) 368.1199; **Found**: 368.1208.

49

Preparation of 3-(diphenylphosphorothioyl)carbazole, 3:

The title compound was prepared in the same way as **2** except elemental sulphur was added as the thionylation agent instead of 30% H_2O_2. White solid. **Yield**: 56%. **R_f:** 0.20 (EA: hexanes = 1:3, silica). **^{1}H NMR (500 MHz, CDCl$_3$) δ (ppm)**: 8.53 (dd, *J* = 14.0, 1.2 Hz, 1 H), 8.35 (br, 1 H), 8.04 (d, *J* = 7.9 Hz, 1 H), 7.82-7.71 (m, 5 H), 7.56-7.46 (m, 9 H), 7.29-7.26 (m, 1 H). **^{13}C NMR (125 MHz, CDCl$_3$) δ (ppm)**: 141.2, 141.2, 139.8, 134.2, 133.5, 132.4, 132.3, 131.4, 131.4, 129.6, 129.5, 128.5, 128.4, 126.8, 125.6, 125.5, 123.5, 123.4, 122.8, 122.4, 121.7, 120.8, 120.4, 110.9, 110.7, 110.6. **^{31}P NMR (202 MHz, CDCl$_3$) δ (ppm)**: 44.35.

Preparation of PPOCzPN, 4:

To a solution of **2** (100 mg, 0.27 mmol, 2 equiv.) in dry THF (5 mL) was added portionwise NaH (60% in mineral oil, 21.6 mg, 0.54 mmol, 4 equiv.) and the mixture was stirred for 15 min. 4,5-difluorophthalonitrile (22.1 mg, 0.14 mmol, 1 equiv.) was added and the mixture was allowed to stir for further 3 h. The mixture was slowly added to ice-water (10 mL) and extracted with DCM (10 mL x 3). The combined organic phase was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatograph using EA:Hexanes (*v/v* = 1:1) as the eluent. The solid obtained was further recrystallized from DCM/Hexanes (*v/v* = 1:9)

50

to afford the analytically pure final product. Light yellow solid. **Yield**: 77%. **R$_f$**: 0.17

(EA, silica). **^{1}H NMR (300 MHz, CDCl$_3$) δ (ppm)**: 8.39 (s, 2 H), 8.21-8.12 (m, 2 H),

7.78-7.48 (m, 22 H), 7.23-6.90 (m, 9 H), 6.73-6.70 (m, 1 H). ^{31}P **NMR (121 MHz,**

CDCl$_3$) δ (ppm): 30.49, 30.39. **HR-MS** (ESI): **[M + H]$^+$ Calculated:** (C$_{56}$H$_{37}$N$_4$O$_2$P$_2$)

5   859.2386; **Found**: 859.2372.

Preparation of PPSCzPN, 5:

The title compound was prepared from **3** in the same way of **4**. Light yellow solid.

Yield: 80%. **R$_f$**: 0.14 (EA: hexanes = 1:3, silica). **^{1}H NMR (300 MHz, CDCl$_3$) δ (ppm)**:

10   8.38 (s, 1 H), 8.37 (s, 1 H), 8.32-8.23 (m, 2 H), 7.80-7.44 (m, 24 H), 7.23-6.93 (m, 7 H),

6.66 (dd, J = 8.6, 2.0 Hz, 1 H). ^{31}P **NMR (121 MHz, CDCl$_3$) δ (ppm)**: 43.64, 43.58. **HR-**

MS (ESI): **[M + H]$^+$ Calculated:** (C$_{56}$H$_{37}$N$_4$S$_2$P$_2$) 819.1929; **Found**: 819.1927.

Preparation of N-tert-butyldimethylsilyl-3,6-dibromocarbazole, 6:

15   The title compound was prepared from 3,6-dibromocarbazole in the same way of

compound **1** according to the published method (Was prepared by the known method

(Chem. Mater., 2015, 27, 6535-6542) (White solid. **Yield**: 95%. **^{1}H NMR (400 MHz,**

CDCl$_3$) δ (ppm): 8.13 (t, J = 1.3 Hz, 2 H), 7.48 (d, J = 1.3 Hz, 4 H), 1.03 (s, 9 H), 0.76

(s, 6 H). ^{13}C **NMR (100 MHz, CDCl$_3$) δ (ppm)**: 144.1, 128.7, 127.1, 122.7, 115.6,

20   112.9, 26.5, 20.6, -1.3.

51

Preparation of 3,6-bis(diphenylphosphoryl)carbazole, **7**:

The title compound was prepared from compound **6** in the same way of **2** except the equivalences of all reagents are correspondingly doubled.

Preparation of diPPOCzPN, **8**:

Compound **8** was prepared from **7** in the same way as **4** and **5** were prepared from **2** and **3**.

52

References:

1.   (a) Uoyama, H.; Goushi, K.; Shizu, K.; Nomura, H.; Adachi, C. *Nature* **2012**, 492, 234; (b) Nakanotani, H.; Higuchi, T.; Furukawa, T.; Masui, K.; Morimoto, K.; Numata, M.; Tanaka, H.; Sagara, Y.; Yasuda, T.; Adachi, C. *Nat Commun* **2014**, 5, 4016; (c) Zhang, Q.; Li, J.; Shizu, K.; Huang, S.; Hirata, S.; Miyazaki, H.; Adachi, C. *J Am Chem Soc* **2012**, 134, 14706; (d) Zhang, Q.; Li, B.; Huang, S.; Nomura, H.; Tanaka, H.; Adachi, C. *Nature Photonics* **2014**, 8, 326.

2.   Reineke, S. *Nature Photonics* **2014**, 8, 269.

3.   a) Lee, S. Y.; Yasuda, T.; Yang, Y. S.; Zhang, Q.; Adachi, C. *Angew Chem Int Ed Engl* **2014**, 53, 6402; (b) Mehes, G.; Nomura, H.; Zhang, Q.; Nakagawa, T.; Adachi, C. *Angew Chem Int Ed Engl* **2012**, 51, 11311.

4.   Uoyama, H.; Goushi, K.; Shizu, K.; Nomura, H.; Adachi, C. *Nature* **2012**, *492*, 234.

5.   Crosby, G. A.; Demas, *J. N. J. Phys. Chem.* **1971**, 75, 991.

6.   Melhuish, W. H. *J. Phys. Chem.* **1961**, 65, 229.

7.   (a) Zhang, J.; Zhou, L.; Al-Attar, H. A.; Shao, K.; Wang, L.; Zhu, D.; Su, Z.; Bryce, M. R.; Monkman, A. P. *Adv. Funct. Mater.* **2013**, 23, 4667; (b) Zheng, Y.; Batsanov, A. S.; Jankus, V.; Dias, F. B.; Bryce, M. R.; Monkman, A. P. *J Org Chem* **2011**, 76, 8300; (c) Yu, W.; Huang, G.; Zhang, Y.; Liu, H.; Dong, L.; Yu, X.; Li, Y.; Chang, J. *J Org Chem 2013*, 78, 10337.

53

CLAIMS

1.   A TADF compound according to formula I:

Het   Het
   \   /
    C—C
   (   )
    C—C
   /   \
  D   D

I

5   wherein the ring II:

   \   /
    C—C
   (   )
    C—C
   /   \

II

represents an aromatic spacer ring with each Het bonded to adjacent carbon atoms
10   and each moiety D bonded to adjacent carbon atoms, and
wherein each Het is an aromatic heterocyclic moiety and each D is a donor moiety.

2.   The TADF compound according to claim 1 wherein the compound is according
to formula III:

15

Het   Het
   \   /
R—   —R
   /   \
  D   D

III
                 wherein R* is , independently for each occurrence, selected from
the group consisting of –H, alkyl, aryl or heteroaryl, the aromatic heterocyclic moieties
Het are, independently for each occurrence selected from the group consisting of:

54

wherein –L represents the bonding position to ring II or III, X represents O, S or NR^2 and groups R^2 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated; substituted or unsubstituted aryl or heteroaryl;

wherein groups R^1 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated; substituted or unsubstituted aryl or heteroaryl, -CF$_3$, -OMe, -SF$_5$, -NO$_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido and carbamate.

3.   The TADF compound according to claim 1 or claim 2 wherein the aromatic heterocyclic moieties Het are 1,3,4 oxadiazoles selected from the group consisting of:


wherein–L represents the bonding position to ring II or III;

-Alkyl represents a substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated; and

wherein groups R^3, R^4 and R^5 are, independently for each occurrence selected from the group consisting of :

-H, substituted or unsubstituted primary, secondary or tertiary alkyl, that may be cyclic and may be unsaturated; substituted or unsubstituted aryl or heteroaryl, -CF$_3$, -OMe, -SF$_5$, -NO$_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide and phosphine sulphide.

4.   The TADF compound according to any preceding claim wherein donor moieties D are independently for each occurrence selected from:

A   B   C

D   E   F

G   H

, and   ;

wherein –L represents the bonding position to ring II or III that is para to the nitrogen in structures C, D, G and H;

X^1 is selected from the group consisting of O, S, NR, SiR$_2$, PR and CR$_2$, wherein each R is independently selected from the group consisting of –H, alkyl, aryl or heteroaryl;

each Ar is independently for each occurrence selected from the group consisting of substituted or unsubstituted aryl or heteroaryl; and

56

represents, independently for each occurrence a substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A B,C, D, E or F, for example a five or a six membered substituted or unsubstituted aryl or heteroaryl ring; and

n ( ) indicates the optional presence of saturated $-CH_2-$ groups in the rings annelated to the benzene ring, wherein n is independently for each occurrence, 0, 1, or 2.

5.   The TADF compound according to claim 4 wherein donor moieties D are independently for each occurrence selected from:


and

wherein $-L$ represents the bonding position to ring II or III;

each group R^6, R^7, R^8 and R^9 is, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide and phosphine sulphide.

57

6.   The TADF compound according to claim 3 selected from the group consisting of:


IV   V   VI

7.   A light emitting device comprising a TADF compound according to any one of claims 1 to 6.

8.   The light emitting device of claim 7, wherein said light emitting device is an OLED.

9.   A TADF compound according to formula Ic:

Ic

wherein the ring II:

II

represents an aromatic spacer ring wherein each Acc is an acceptor moiety with each acceptor moiety Acc bonded to adjacent carbon atoms, each D is a donor moiety and each donor moiety D bonded to adjacent carbon atoms, and

58

wherein one of the donor moieties D is according to formula A and the other is according to formula A or according to formula B :

A   B

5   wherein –L represents the bonding position to ring II;

X^1 is selected from the group consisting of O, S, NR and CR_2, wherein each R is independently selected from the group consisting of –H, alkyl, aryl or heteroaryl, for example substituted or unsubstituted C1-C20 or even C1-C10; and


represents, independently for each occurrence a substituted or
10   unsubstituted aryl or heteroaryl ring fused to the central ring of structures A or B.

10. The TADF compound according to claim 9 wherein ⌒Ar⌒ represents, independently for each occurrence a five or a six membered substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A or B.

15

11.   The TADF compound according to claim 9 or claim 10 wherein the compound of formula Ic is be according to formula IIIc:


IIIc   wherein R* is, independently for each occurrence, selected from
20   the group consisting of –H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10.

59

12.   The TADF compound according to any one of claims 9 to 11 wherein the acceptor moieties Acc are, independently for each occurrence selected from the group consisting of -Het as defined in claim 2, -CN, sulfone, sulfoxide, imine, amide, acridine, acridinium, carboxylate ester, phosphine oxide, phosphine sulfide, ketone and
5   aldehyde.

13.   The TADF compound according to any one of claims 9 to 12 wherein the donor moieties D of formula A in formula Ic are selected from:


10

wherein the group R has the same meaning as in claim 9 and each group R^6, R^7, R^8 and R^9 is, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated); substituted or unsubstituted aryl or heteroaryl, -CF_3, -OMe, -SF_5,
15   -NO_2, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide and phosphine sulphide.

14.   The TADF compound according to claim 9 selected from the group consisting of
20   formulas VIII, IX and X:

VIII   IX   X

60

15.   A light emitting device comprising a TADF compound according to any one of claims 9 to 15.

16.   The light emitting device of claim 15, wherein said light emitting device is an OLED.

17.   A charged organic TADF species according to formula Ia:

Ia

wherein the ring II:

II

represents an aromatic spacer ring with each Het bonded to adjacent carbon atoms and each moiety D bonded to adjacent carbon atoms;

wherein each Het is an aromatic heterocyclic moiety and each D is a donor moiety and sufficient counter ions C are provided to balance the charge on the species according to formula Ia.

18.   The charged organic species according to claim 17 having formula Ib and associated counter ions C:

    nC

Ib

61

wherein C is a counter ion with opposite charge to that provided on the ring structure including the groups Het and D, and n is at least one.

19.   The charged organic species according to claim 17 having formula IIIa:

IIIa   wherein D and Het have the same meaning as for formula Ia. R* is, independently for each occurrence, selected from the group consisting of –H, alkyl, aryl or heteroaryl, for example substituted or unsubstituted C1-C20 or even C1-C10; the aromatic heterocyclic moieties Het are, independently for each occurrence selected from the group consisting of:

and

wherein –L represents the bonding position to ring IIIa, X represents O, S or NR^2 and groups R^2 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl;

wherein groups R^1 are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, -CF_3, -OMe,   -SF_5, -NO_2, halo (e.g. fluoro, chloro, bromo and iodo), aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy,

62

cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido, carbamate, phosphine oxide and phosphine sulphide;

and wherein at least one of the occurrences R^* and R^1 represents the bonding position, either directly or via a linking group L, to a charged group Z

5   and/or at least one of the donor moieties D includes a charged group Z directly attached or attached via a linking group L.

20.   The charged organic species according to claim 19 wherein at least one linking group L is present and is independently for each occurrence, a hydrocarbylene chain,

10   that may be substituted or unsubstituted, hydrocarbylene or unsaturated hydrocarbylene.

21. The charged organic species according to claim 20 wherein the at least one linking group L is selected from substituted or unsubstituted cyclopentane-1,3-diyl,

15   cyclohexane-1,4-diyl, 1,4-phenylene and 4,4'-biphenylene.

22.   The charged organic species according to claim 20 wherein the at least one linking group L is selected from : $-CH_2\left(CH_2\right)_n$

20   , wherein n is from 0 to 10 or even 0 to 5 and optionally containing one or more unsaturations; cyclopentane-1,3-diyl; cyclohexane-1,4-diyl; 1,4-phenylene; and 4,4'-biphenylene.

23.   The charged organic species according to any one of claims 19 to 22 wherein

25   charged groups Z are independently for each occurrence, selected from the group consisting of quaternary nitrogen cations and quaternary phosphorus cations.

24.   The charged organic species according to any one of claims 19 to 22 wherein charged groups Z are organic groups provided with anionic substituents selected from

30   the group consisting of carboxylate, sulfonate, sulfinate, phosphonate, cyanide and thiocyanate.

26.   The charged organic species according to any one of claims 19 to 23 wherein charged groups Z are independently for each occurrence, selected from the group

35   consisting of:

63

wherein –L indicates the position of bonding to a linking group L or directly to a charged moiety of formula IIIa; R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{10} are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido and carbamate.

27.   The charged organic species according to any one of claims 19 to 23 wherein at least one charged group Z is according to structure 5:

5

wherein one of R^8, R^9, R^{10} and R^{11} bonds to a linking group L or directly to a TADF moiety and the others of R^8, R^9, R^{10} and R^{11}, independently for each occurrence

64

selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, -SF_5, $-NO_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido and carbamate.

28.   The charged organic species according to any one of claims 19 to 23 wherein at least one charged group Z is according to structure 6:

$$R^1 - \overset{\overset{\displaystyle R^2}{|}}{\underset{\underset{\displaystyle R^3}{|}}{\overset{\oplus}{P}}} - L$$

6

wherein –L indicates the position of bonding to a linking group L or directly to a charged moiety of formula IIIa; R^1, R^2 and R^3, are, independently for each occurrence, selected from the group consisting of -H, substituted or unsubstituted primary , secondary or tertiary alkyl, that may be cyclic and may be unsaturated (for example C1-C10 or even C1-C4); substituted or unsubstituted aryl or heteroaryl, $-CF_3$, -OMe, $-SF_5$, $-NO_2$, halo, aryl, aryl hydroxy, amino, alkoxy, alkylthio, carboxy, cyano, thio, formyl, ester, acyl, thioacyl, amido, sulfonamido and carbamate.

29.   The charged organic species according to any one of claims 18 to 28 wherein counter ions C are selected from the group consisting of: halide, PF_6^-, BF_4^- , BR_4^- ; wherein R is an aryl group, for example phenyl; OTf^-, OTs^-, SbX_6^- wherein X is halide, NTf_2^- NO_3^-, CO_3^{2-}; cations of first and second group elements in the periodic table and quaternary ammonium cations.

30.   A light emitting device comprising a TADF species according to any one of claims 17 to 29.

31.   The light emitting device of claim 30, wherein said light emitting device is an LEEC or an OLED.

65

32.   A TADF compound wherein at least one donor moiety (D) is substituted by at least one substituent selected from the group consisting of phosphine oxide and phosphine sulphide.

33.   The TADF compound of claim 32 wherein more than one phosphine oxide or phosphine sulphide substituent is provided and they are the same.

34.   The TADF compound of claim 32 wherein each donor moiety (D) is provided with a phosphine oxide or phosphine sulphide substituent.

35.   The TADF compound of any one of claims 32 to 34 wherein the phosphine oxide or phosphine sulphide substituent(s) are selected from the group consisting of:

and   where the substituents R on the phosphorus may be alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10).

36.   The TADF compound of claim 35 wherein the phosphine oxide or phosphine sulphide substituent(s) have phenyl or substituted phenyl groups R on the phosphorus.

37.   The TADF compound of claim 35 according to formula Id:


Id

wherein the ring II:

II

represents an aromatic spacer ring wherein each Acc is an acceptor moiety with each acceptor moiety Acc bonded to adjacent carbon atoms, each D is a donor moiety and each donor moiety D bonded to adjacent carbon atoms, and

wherein the donor moieties D are independently selected from the group consisting of

5   formula A and formula B :

A   B

wherein –L represents the bonding position to ring II;

X^1 is selected from the group consisting of O, S, NR, SiR_2, PR and CR_2,

10   wherein each R is independently selected from the group consisting of –H, alkyl, aryl or heteroaryl (for example substituted or unsubstituted C1-C20 or even C1-C10); and

represents, independently for each occurrence a substituted or unsubstituted aryl or heteroaryl ring fused to the central ring of structures A or B, for example a five or a six membered substituted or unsubstituted aryl or heteroaryl ring; and wherein

15   at least one substituent on at least one   present in the compound is phosphine oxide or phosphine sulphide.

Fig. 1

Ca(20 nm)/Al (100 nm)
B3PYMPM (50 nm)
Emissive layer (~ 30 nm)
PVK (30 nm)
PEDOT:PSS (30 nm)
ITO
Glass

Fig. 2

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07F9/572   C07D413/10   C07D417/10   C09K11/06   H01L33/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07F C07D C09K H01L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HIROKI UOYAMA ET AL: "Highly efficient organic light-emitting diodes from delayed fluorescence", NATURE, vol. 492, no. 7428, 12 December 2012 (2012-12-12), pages 234-238, XP055048388, ISSN: 0028-0836, DOI: 10.1038/nature11687 cited in the application compound 4CzTPN -/--	1,4,5,7,8

[X] Further documents are listed in the continuation of Box C.   [X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 March 2016	20/06/2016

| Name and mailing address of the ISA/
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016 | Authorized officer

 Duval, Eric |

Form PCT/ISA/210 (second sheet) (April 2005)

1

C(Continuation).	DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	COLIN J. MARTIN ET AL: "Oxidative Bond Formation in Dithienyl Polyphenylenes: Optical and Electrochemical Consequences", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2011, no. 19, 24 July 2011 (2011-07-24), pages 3491-3499, XP055261057, DE ISSN: 1434-193X, DOI: 10.1002/ejoc.201100332 compounds 1, 2 -----	1
X,P	WO 2015/175678 A1 (HARVARD COLLEGE [US]) 19 November 2015 (2015-11-19) compounds F9, F10, G12, G13, G66, H10 -----	1,2,4,5, 7,8
A,P	MICHAEL Y. WONG ET AL: "Light-Emitting Electrochemical Cells and Solution-Processed Organic Light-Emitting Diodes Using Small Molecule Organic Thermally Activated Delayed Fluorescence Emitters", CHEMISTRY OF MATERIALS, vol. 27, no. 19, 14 July 2015 (2015-07-14) , pages 6535-6542, XP055257653, US ISSN: 0897-4756, DOI: 10.1021/acs.chemmater.5b03245 the whole document -----	1-8

1

INTERNATIONAL SEARCH REPORT

Box No. II   Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III   Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of
additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-8

Remark on Protest   ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the
payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest
fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (April 2005)

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-8

   TADF compounds of formula I and light-emitting devices comprising the same

   ---

2. claims: 9-16

   TADF compounds of formula Ic and light-emitting devices comprising the same

   ---

3. claims: 17-31

   TADF compounds of formula Ia and light-emitting devices comprising the same

   ---

4. claims: 32-37

   TADF compounds comprising a a phosphine oxide or phosphine sulphide

   ---

INTERNATIONAL SEARCH REPORT
Information on patent family members

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015175678 A1	19-11-2015	NONE	